Significance of PD‑L1 in the diagnosis and treatment of B‑cell malignant lymphoma

Yang,Jianzhong; Hu,Guangzhu

doi:10.3892/ol.2019.9982

Significance of PD‑L1 in the diagnosis and treatment of B‑cell malignant lymphoma

Authors:
- Jianzhong Yang
- Guangzhu Hu
View Affiliations

Affiliations: Department of Hematopathology, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, Fujian 362000, Department of Cardiothoracic Surgery, Suizhou Central Hospital, Suizhou, Hubei 441300, P.R. China
Published online on: January 28, 2019 https://doi.org/10.3892/ol.2019.9982
Pages: 3382-3386
Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study explored the significance of programmed death‑ligand 1 (PD‑L1) molecules in the diagnosis and treatment of B‑cell malignant lymphoma. A total of 92 patients with B‑cell malignant lymphoma (experimental group), admitted to the Quanzhou First Hospital Affiliated to Fujian Medical University from February 2014 to May 2017, and 60 healthy subjects (control group) were enrolled in this study and their clinical data were retrospectively analyzed. Plasma levels of PD‑L1 before treatment and at 5, 10, and 15 days after treatment were measured by ELISA. Correlation between PD‑L1 expression levels and treatment time was analyzed. Levels of PD‑L1 in different pathological types were compared. ROC curve was used to analyze the efficacy of PD‑L1 in the treatment of B‑cell lymphoma. The expression level of PD‑L1 in experimental group was 272.86±48.21 pg/ml, significantly higher than that in control group (18.24±3.62 pg/ml) (P<0.01). In patients with B‑cell lymphoma, PD‑L1 expression was highest in diffuse large B‑cell lymphoma, followed by small lymphocyte lymphoma, mucosa‑associated lymphoid tissue lymphoma, mantle cell lymphoma, and the lowest PD‑L1 expression level was observed in follicular lymphoma (P<0.05). Linear correlation analysis showed that the expression level of PD‑L1 was negatively correlated with treatment time (r=‑0.683, P<0.01).The highest Youden index (51.24) was set as cut‑off score, the sensitivity of the diagnosis of B‑cell lymphoma was 81.66%, and the specificity was 90.24%. PD‑L1 is highly expressed in B‑cell malignant lymphomas and negatively correlated with treatment time. It has high diagnostic efficiency for B‑cell lymphoma and is expected to be an effective immunotherapeutic target for B‑cell lymphoma.

View Figures

View References

1	Lesokhin AM, Ansell SM, Armand P, Scott EC, Halwani A, Gutierrez M, Millenson MM, Cohen AD, Schuster SJ, Lebovic D, et al: Nivolumab in patients with relapsed or refractory hematologic malignancy: Preliminary results of a phase Ib study. J Clin Oncol. 34:2698–2704. 2016. View Article : Google Scholar : PubMed/NCBI
2	Kirkegaard MM, Coupland SE, Prause JU and Heegaard S: Malignant lymphoma of the conjunctiva. Surv Ophthalmol. 60:444–458. 2015. View Article : Google Scholar : PubMed/NCBI
3	Armitage JO, Gascoyne RD, Lunning MA and Cavalli F: Non-Hodgkin lymphoma. Lancet. 390:298–310. 2017. View Article : Google Scholar : PubMed/NCBI
4	Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, Yang JC, Phan GQ, Hughes MS, Sherry RM, et al: Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 33:540–549. 2015. View Article : Google Scholar : PubMed/NCBI
5	Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, Lih CJ, Williams PM, Shaffer AL, Gerecitano J, et al: Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 21:922–926. 2015. View Article : Google Scholar : PubMed/NCBI
6	Tilly H, Gomes da Silva M, Vitolo U, Jack A, Meignan M, Lopez-Guillermo A, Walewski J, André M, Johnson PW, Pfreundschuh M, et al: ESMO Guidelines Committee: Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 26 Suppl 5:v116–v125. 2015. View Article : Google Scholar : PubMed/NCBI
7	Scott DW, Mottok A, Ennishi D, Wright GW, Farinha P, Ben-Neriah S, Kridel R, Barry GS, Hother C, Abrisqueta P, et al: Prognostic significance of diffuse large B-cell lymphoma cell of origin determined by digital gene expression in formalin-fixed paraffin-embedded tissue biopsies. J Clin Oncol. 33:2848–2856. 2015. View Article : Google Scholar : PubMed/NCBI
8	Sehn LH and Gascoyne RD: Diffuse large B-cell lymphoma: Optimizing outcome in the context of clinical and biologic heterogeneity. Blood. 125:22–32. 2015. View Article : Google Scholar : PubMed/NCBI
9	Choi J, Goh G, Walradt T, Hong BS, Bunick CG, Chen K, Bjornson RD, Maman Y, Wang T, Tordoff J, et al: Genomic landscape of cutaneous T cell lymphoma. Nat Genet. 47:1011–1019. 2015. View Article : Google Scholar : PubMed/NCBI
10	Birge RB, Boeltz S, Kumar S, Carlson J, Wanderley J, Calianese D, Barcinski M, Brekken RA, Huang X, Hutchins JT, et al: Phosphatidylserine is a global immunosuppressive signal in efferocytosis, infectious disease, and cancer. Cell Death Differ. 23:962–978. 2016. View Article : Google Scholar : PubMed/NCBI
11	McDermott DF, Sosman JA, Sznol M, Massard C, Gordon MS, Hamid O, Powderly JD, Infante JR, Fassò M, Wang YV, et al: Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: Long-term safety, clinical activity, and immune correlates from a phase Ia study. J Clin Oncol. 34:833–842. 2016. View Article : Google Scholar : PubMed/NCBI
12	Kim S, Kim MY, Koh J, Go H, Lee DS, Jeon YK and Chung DH: Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas. Eur J Cancer. 51:2698–2707. 2015. View Article : Google Scholar : PubMed/NCBI
13	Cedrés S, Ponce-Aix S, Zugazagoitia J, Sansano I, Enguita A, Navarro-Mendivil A, Martinez-Marti A, Martinez P and Felip E: Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). PLoS One. 10:e01210712015. View Article : Google Scholar : PubMed/NCBI
14	Pregno P, Chiappella A, Bellò M, Botto B, Ferrero S, Franceschetti S, Giunta F, Ladetto M, Limerutti G, Menga M, et al: Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. Blood. 119:2066–2073. 2012. View Article : Google Scholar : PubMed/NCBI
15	Schumacher TN and Schreiber RD: Neoantigens in cancer immunotherapy. Science. 348:69–74. 2015. View Article : Google Scholar : PubMed/NCBI
16	Patel SP and Kurzrock R: PD-L1 Expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 14:847–856. 2015. View Article : Google Scholar : PubMed/NCBI
17	Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y and Zang X: Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med. 21:24–33. 2015. View Article : Google Scholar : PubMed/NCBI
18	Kranz LM, Diken M, Haas H, Kreiter S, Loquai C, Reuter KC, Meng M, Fritz D, Vascotto F, Hefesha H, et al: Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature. 534:396–401. 2016. View Article : Google Scholar : PubMed/NCBI
19	Howitt BE, Shukla SA, Sholl LM, Ritterhouse LL, Watkins JC, Rodig S, Stover E, Strickland KC, D'Andrea AD, Wu CJ, et al: Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. JAMA Oncol. 1:1319–1323. 2015. View Article : Google Scholar : PubMed/NCBI
20	Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 366:2455–2465. 2012. View Article : Google Scholar : PubMed/NCBI
21	Muro K, Chung HC, Shankaran V, Geva R, Catenacci D, Gupta S, Eder JP, Golan T, Le DT, Burtness B, et al: Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): A multicentre, open-label, phase 1b trial. Lancet Oncol. 17:717–726. 2016. View Article : Google Scholar : PubMed/NCBI
22	Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, et al: Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet. 387:1540–1550. 2016. View Article : Google Scholar : PubMed/NCBI